GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Net-Net Working Capital

Procaps Group (Procaps Group) Net-Net Working Capital : $-2.53 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Procaps Group's Net-Net Working Capital for the quarter that ended in Sep. 2023 was $-2.53.

The industry rank for Procaps Group's Net-Net Working Capital or its related term are showing as below:

PROC's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.895
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Procaps Group Net-Net Working Capital Historical Data

The historical data trend for Procaps Group's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Net-Net Working Capital Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net-Net Working Capital
-4.21 -4.56 -2.76 -2.52

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.52 -2.51 -2.60 -2.53

Competitive Comparison of Procaps Group's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Procaps Group's Price-to-Net-Net-Working-Capital falls into.



Procaps Group Net-Net Working Capital Calculation

Procaps Group's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(43.003+0.75 * 114.391+0.5 * 96.833-462.065
-0--0.937)/112.824
=-2.52

Procaps Group's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2023 is calculated as

Net-Net Working Capital(Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(25.831+0.75 * 131.709+0.5 * 98.242-460.1
-0--0.932)/112.824
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Procaps Group  (NAS:PROC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Procaps Group Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Procaps Group's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371